

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Anders PETTERSSON et al.

Serial No. (unknown)

Filed herewith

PHARMACEUTICAL COMPOSITION
FOR THE TREATMENT OF ACUTE
DISORDERS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In compliance with Rules 1.97 and 1.98, and in fulfillment of the duty of disclosure under Rule 1.56, the accompanying documents, copies of which are attached to this statement, are made of record on the enclosed sheet.

A concise explanation of the relevance of these items is that these references were cited by the Swedish Patent Office in the corresponding International application No. PCT/SE99/01687, filed September 24, 1999.

Respectfully submitted,

YOUNG & THOMPSON

By Benoît Castel
Benoît Castel
Attorney for Applicants
Customer No. 000466
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

March 26, 2001

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
103364702USSERIAL NO.
097787888**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Anders PETTERSSON and Christer
NYSTROMFILING DATE
March 26, 2001

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AG	EP 0 144 243	06/85	Europe			Yes
	AH	EP 0 324 725	07/89	Europe			Yes
	AI						
	AJ						
	AK						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

	AL	Farrar JT et al. "Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients", J Natl Cancer Inst (United States) Apr 15 1998, Vol. 90, No. 8, pp 611-6
	AM	
	AN	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.